This week we interviewed Dr. Domingo, Professor at the University of Barcelona, from the Department of Biochemistry and Molecular Biomedicine, and one of the leading European experts in lipid science.
Dr. Domingo, can you explain what obesity-related inflammation is?
Lipoinflammation in the context of obesity is a low-grade inflammation that originates in adipose tissue as a result of its uncontrolled growth and that extends to other tissues. Furthermore, the lack of resolution of the inflammatory process makes it chronic over time.
Why is it important to control it in the context of weight management?
During weight loss associated with a treatment, it is important to simultaneously resolve the chronic inflammation generated, as there are different published studies indicating that the non-resolution of said inflammation can be an important factor in post-treatment weight regain.
Can this inflammation be improved with anti-inflammatory fats like Omega-3s?
Omega-3 fatty acids, mainly long-chain EPA and DHA, have been shown to be the substrates for molecules called resolvins and protectins, which are precisely responsible for resolving inflammation and returning it to its basal state. As is perfectly accepted by the scientific community, there is a deficit in the intake of DHA and EPA in our society that facilitates the development of pathologies associated with chronic inflammation. Therefore, an interesting nutritional strategy is to increase the intake of DHA and EPA in these patients to facilitate the synthesis of resolvins and protectins, which ultimately should facilitate the resolution of inflammation.
Among Omega-3s, which do you consider the most suitable or with the most scientific evidence?
In the current context, i.e., in a long-term chronic treatment and according to the different published studies, without a doubt the best choice is DHA, since it is more accumulative in terms of reserves, it is more versatile and it is more potent than EPA.
Brudy's DHA has demonstrated its antioxidant and anti-inflammatory power in numerous clinical trials, when the response to its supplementation in various health areas has been analyzed, decreasing the production of pro-inflammatory cytokines and helping to control insulin, as well as decreasing liver fat. Do you consider it a good candidate to treat obesity-related inflammation?
Brudy's DHA meets the necessary requirements, both structurally and functionally, to be used with full guarantees in the context of treating obesity-related inflammation. Published studies have shown that it is a product with high bioavailability due to its lipid composition and with high bioactivity demonstrated both in vitro and in vivo, which has been manifested in its anti-inflammatory capacity. Furthermore, it is the only one, as far as I know, that has demonstrated cellular antioxidant capacity, which guarantees biosafety.
Thank you very much, Dr. Domingo, for once again contributing your knowledge to the dissemination of science in the area of health and nutrition.
